SEP 8, 2026 · PHASE 1/2 TRIAL
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
ClinicalTrials.gov
This is a Phase 1/2 trial registration with recruitment suspended; no results are posted, making it an early-stage study design record without outcome data.
Reported
Estimated enrollment30
PhasePhase 1/2
Primary outcome measure (Phase II)Frequency of immunologic responses to purif…